- Home
- OTLY vs NPCE Comparison
OTLY vs NPCE Comparison
Compare OTLY & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | NPCE |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 328.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTLY | NPCE |
|---|---|---|
| Price | $11.68 | $16.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $15.50 | ★ $17.29 |
| AVG Volume (30 Days) | 63.1K | ★ 248.7K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $842,996,000.00 | $94,864,000.00 |
| Revenue This Year | $4.69 | $24.82 |
| Revenue Next Year | $4.65 | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.63 | ★ 24.08 |
| 52 Week Low | $6.00 | $7.56 |
| 52 Week High | $18.84 | $18.98 |
Technical Indicators
Market Signals| Indicator | OTLY | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 62.47 |
| Support Level | $11.56 | $16.00 |
| Resistance Level | $12.43 | $16.94 |
| Average True Range (ATR) | 0.51 | 0.80 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 11.63 | 68.23 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.